Ann: Investor Presentation, page-15

Personally I don't think this is as terrible result as people are making it out to be.
Sure the covid opportunity hasn't been the rocket we might have hoped for, but at this stage Atomo is still carrying strong cash reserves, developing multiple lines of products/sales, each with a good growth outlook. I think Febridx has huge potential as does the Mylan partnership.
Sure the share price is all over the show due to speculation, but the company is behaving maturely, achieving stable, healthy growth.

Covid tests sold in H1 around 420k ($4.51m rev). This was beaten in January of Q3 alone, so if this level of sales holds stable, the company is on track to $27m rev for H2, or 31.5m for the full year just from Covid.

Tack on HIV self test sales and Febridx, which are both at the exciting end of an adoption curve and I am still feeling like this is a buy at this price.